This HTML5 document contains 202 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/wikipedia/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/kegg-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/bindingdb/
foafhttp://xmlns.com/foaf/0.1/
n31http://linked.opendata.cz/resource/mesh/concept/
n5http://linked.opendata.cz/resource/drugbank/company/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/pubchem-compound/
n12http://linked.opendata.cz/resource/drugbank/dosage/
n29http://linked.opendata.cz/resource/drugbank/mixture/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/drugbank/
n26http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n21http://www.rxlist.com/cgi/generic/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/national-drug-code-directory/
n27http://linked.opendata.cz/resource/drugbank/patent/
n32http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n24http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n30http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n28http://www.drugs.com/cdi/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00465/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
n23http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00465
rdf:type
n3:Drug
n3:description
A pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
n3:dosage
n12:271B5705-363D-11E5-9242-09173F13E4C5 n12:271B5706-363D-11E5-9242-09173F13E4C5 n12:271B5707-363D-11E5-9242-09173F13E4C5 n12:271B5708-363D-11E5-9242-09173F13E4C5 n12:271B5709-363D-11E5-9242-09173F13E4C5 n12:271B570A-363D-11E5-9242-09173F13E4C5 n12:271B570B-363D-11E5-9242-09173F13E4C5 n12:271B56FD-363D-11E5-9242-09173F13E4C5 n12:271B56FE-363D-11E5-9242-09173F13E4C5 n12:271B56FF-363D-11E5-9242-09173F13E4C5 n12:271B5700-363D-11E5-9242-09173F13E4C5 n12:271B5701-363D-11E5-9242-09173F13E4C5 n12:271B5702-363D-11E5-9242-09173F13E4C5 n12:271B5703-363D-11E5-9242-09173F13E4C5 n12:271B5704-363D-11E5-9242-09173F13E4C5 n12:271B56F8-363D-11E5-9242-09173F13E4C5 n12:271B56F9-363D-11E5-9242-09173F13E4C5 n12:271B56FA-363D-11E5-9242-09173F13E4C5 n12:271B56FB-363D-11E5-9242-09173F13E4C5 n12:271B56FC-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer
n3:indication
For the short-term (~5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
n3:manufacturer
n5:271B56DF-363D-11E5-9242-09173F13E4C5 n5:271B56E0-363D-11E5-9242-09173F13E4C5 n5:271B56CD-363D-11E5-9242-09173F13E4C5 n5:271B56CE-363D-11E5-9242-09173F13E4C5 n5:271B56CB-363D-11E5-9242-09173F13E4C5 n5:271B56CC-363D-11E5-9242-09173F13E4C5 n5:271B56C9-363D-11E5-9242-09173F13E4C5 n5:271B56CA-363D-11E5-9242-09173F13E4C5 n5:271B56C7-363D-11E5-9242-09173F13E4C5 n5:271B56C8-363D-11E5-9242-09173F13E4C5 n5:271B56DD-363D-11E5-9242-09173F13E4C5 n5:271B56DE-363D-11E5-9242-09173F13E4C5 n5:271B56DB-363D-11E5-9242-09173F13E4C5 n5:271B56DC-363D-11E5-9242-09173F13E4C5 n5:271B56D9-363D-11E5-9242-09173F13E4C5 n5:271B56DA-363D-11E5-9242-09173F13E4C5 n5:271B56D7-363D-11E5-9242-09173F13E4C5 n5:271B56D8-363D-11E5-9242-09173F13E4C5 n5:271B56D5-363D-11E5-9242-09173F13E4C5 n5:271B56D6-363D-11E5-9242-09173F13E4C5 n5:271B56D3-363D-11E5-9242-09173F13E4C5 n5:271B56D4-363D-11E5-9242-09173F13E4C5 n5:271B56D1-363D-11E5-9242-09173F13E4C5 n5:271B56D2-363D-11E5-9242-09173F13E4C5 n5:271B56CF-363D-11E5-9242-09173F13E4C5 n5:271B56D0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n26:DB00465 n32:DB00465
dcterms:title
Ketorolac
adms:identifier
n10:Ketorolac n13:PA450150 n14:3826 n15:C07062 n16:68387-440-20 n17:DB00465 n18:50009855 n19:3694 n22:46507019
n3:mechanismOfAction
Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) chemically related to indomethacin and tolmetin. Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medications. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity. However, inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation may also contribute to the analgesic effect. In terms of the ophthalmic applications of ketorolac - ocular administration of ketorolac reduces prostaglandin E2 levels in aqueous humor, secondary to inhibition of prostaglandin biosynthesis.
n3:packager
n5:271B56B1-363D-11E5-9242-09173F13E4C5 n5:271B56B2-363D-11E5-9242-09173F13E4C5 n5:271B56AF-363D-11E5-9242-09173F13E4C5 n5:271B56B0-363D-11E5-9242-09173F13E4C5 n5:271B56B5-363D-11E5-9242-09173F13E4C5 n5:271B56B6-363D-11E5-9242-09173F13E4C5 n5:271B56B3-363D-11E5-9242-09173F13E4C5 n5:271B56B4-363D-11E5-9242-09173F13E4C5 n5:271B56B9-363D-11E5-9242-09173F13E4C5 n5:271B56BA-363D-11E5-9242-09173F13E4C5 n5:271B56B7-363D-11E5-9242-09173F13E4C5 n5:271B56B8-363D-11E5-9242-09173F13E4C5 n5:271B56BD-363D-11E5-9242-09173F13E4C5 n5:271B56BE-363D-11E5-9242-09173F13E4C5 n5:271B56BB-363D-11E5-9242-09173F13E4C5 n5:271B56BC-363D-11E5-9242-09173F13E4C5 n5:271B56A1-363D-11E5-9242-09173F13E4C5 n5:271B56A2-363D-11E5-9242-09173F13E4C5 n5:271B569F-363D-11E5-9242-09173F13E4C5 n5:271B56A0-363D-11E5-9242-09173F13E4C5 n5:271B56A5-363D-11E5-9242-09173F13E4C5 n5:271B56A6-363D-11E5-9242-09173F13E4C5 n5:271B56A3-363D-11E5-9242-09173F13E4C5 n5:271B56A4-363D-11E5-9242-09173F13E4C5 n5:271B56A9-363D-11E5-9242-09173F13E4C5 n5:271B56AA-363D-11E5-9242-09173F13E4C5 n5:271B56A7-363D-11E5-9242-09173F13E4C5 n5:271B56A8-363D-11E5-9242-09173F13E4C5 n5:271B56AD-363D-11E5-9242-09173F13E4C5 n5:271B56AE-363D-11E5-9242-09173F13E4C5 n5:271B56AB-363D-11E5-9242-09173F13E4C5 n5:271B56AC-363D-11E5-9242-09173F13E4C5 n5:271B56C1-363D-11E5-9242-09173F13E4C5 n5:271B56C2-363D-11E5-9242-09173F13E4C5 n5:271B56BF-363D-11E5-9242-09173F13E4C5 n5:271B56C0-363D-11E5-9242-09173F13E4C5 n5:271B56C5-363D-11E5-9242-09173F13E4C5 n5:271B56C6-363D-11E5-9242-09173F13E4C5 n5:271B56C3-363D-11E5-9242-09173F13E4C5 n5:271B56C4-363D-11E5-9242-09173F13E4C5 n5:271B5692-363D-11E5-9242-09173F13E4C5 n5:271B5695-363D-11E5-9242-09173F13E4C5 n5:271B5696-363D-11E5-9242-09173F13E4C5 n5:271B5693-363D-11E5-9242-09173F13E4C5 n5:271B5694-363D-11E5-9242-09173F13E4C5 n5:271B5699-363D-11E5-9242-09173F13E4C5 n5:271B569A-363D-11E5-9242-09173F13E4C5 n5:271B5697-363D-11E5-9242-09173F13E4C5 n5:271B5698-363D-11E5-9242-09173F13E4C5 n5:271B569D-363D-11E5-9242-09173F13E4C5 n5:271B569E-363D-11E5-9242-09173F13E4C5 n5:271B569B-363D-11E5-9242-09173F13E4C5 n5:271B569C-363D-11E5-9242-09173F13E4C5
n3:patent
n27:5110493 n27:6333044 n27:1328614
n3:routeOfElimination
The principal route of elimination of ketorolac and its metabolites is renal. Approximately 6% of a dose is excreted in the feces.
n3:synonym
Kétorolac Ketorolacum Ketorolac rac-Ketorolac (+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid (+-)-Ketorolac Ketorolaco
n3:toxicity
LD<sub>50</sub> = 189 mg/kg (rat, oral).
n3:volumeOfDistribution
* 0.26 ± 0.08 L/kg [children 4 to 8 years old]
n6:hasAHFSCode
n7:28-08-04-92 n7:52-08-20
n3:foodInteraction
Take with food to reduce GI irritation
n3:mixture
n29:271B5691-363D-11E5-9242-09173F13E4C5 n29:271B568F-363D-11E5-9242-09173F13E4C5 n29:271B5690-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
99%
n3:salt
n3:synthesisReference
Peter J. Harrington, Hiralal N. Khatri, George C. Schloemer, "Preparation of ketorolac." U.S. Patent US6323344, issued October, 1989.
n30:hasConcept
n31:M0112721
foaf:page
n21:ketor.htm n23:acu1644.shtml n28:ketorolac-drops.html
n3:IUPAC-Name
n4:271B5710-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5716-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5715-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5712-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5713-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5714-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5726-363D-11E5-9242-09173F13E4C5 n4:271B570E-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5728-363D-11E5-9242-09173F13E4C5 n4:271B570C-363D-11E5-9242-09173F13E4C5 n4:271B570F-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B570D-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n11:M01AB15 n11:S01BC05
n3:H-Bond-Acceptor-Count
n4:271B571C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B571D-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5717-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5718-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B571A-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5719-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B571B-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and completely absorbed after oral administration
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
66635-83-4
n3:category
n3:clearance
* 0.042 +/- 0.01 L/hr/kg [Pediatric Patients] * 0.02 L/h/kg [Normal Subjects IM] * 0.03 L/h/kg [Normal Subjects oral] * 0.02 L/h/kg [Healthy Elderly Subjects IM] * 0.02 L/h/kg [Healthy Elderly Subjects oral] * 0.03 L/h/kg [Patients with Hepatic Dysfunction IM] * 0.03 L/h/kg [Patients with Hepatic Dysfunction oral] * 0.02 L/h/kg [Patients with Renal Impairment IM] * 0.02 L/h/kg [Patients with Renal Impairment oral] * 0.02 L/h/kg [Renal Dialysis Patients IM]
n3:containedIn
n24:271B56E1-363D-11E5-9242-09173F13E4C5 n24:271B56E3-363D-11E5-9242-09173F13E4C5 n24:271B56E4-363D-11E5-9242-09173F13E4C5 n24:271B56E2-363D-11E5-9242-09173F13E4C5 n24:271B56F7-363D-11E5-9242-09173F13E4C5 n24:271B56F5-363D-11E5-9242-09173F13E4C5 n24:271B56F6-363D-11E5-9242-09173F13E4C5 n24:271B56E7-363D-11E5-9242-09173F13E4C5 n24:271B56E8-363D-11E5-9242-09173F13E4C5 n24:271B56E5-363D-11E5-9242-09173F13E4C5 n24:271B56E6-363D-11E5-9242-09173F13E4C5 n24:271B56EB-363D-11E5-9242-09173F13E4C5 n24:271B56EC-363D-11E5-9242-09173F13E4C5 n24:271B56E9-363D-11E5-9242-09173F13E4C5 n24:271B56EA-363D-11E5-9242-09173F13E4C5 n24:271B56EF-363D-11E5-9242-09173F13E4C5 n24:271B56F0-363D-11E5-9242-09173F13E4C5 n24:271B56ED-363D-11E5-9242-09173F13E4C5 n24:271B56EE-363D-11E5-9242-09173F13E4C5 n24:271B56F3-363D-11E5-9242-09173F13E4C5 n24:271B56F4-363D-11E5-9242-09173F13E4C5 n24:271B56F1-363D-11E5-9242-09173F13E4C5 n24:271B56F2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5722-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5724-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5725-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5727-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5721-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5720-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5723-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5711-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B571E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B571F-363D-11E5-9242-09173F13E4C5